Form 4: Leap Therapeutics Director Acquires Stock Options

Christian M. Richard, a director of Leap Therapeutics, acquired stock options for 25,000 shares on October 2, 2024.

Summary

• On October 2, 2024, Christian M. Richard, a director of Leap Therapeutics, acquired stock options for 25,000 shares.
• The options have an exercise price of $2.45.
• The options were granted under Leap's 2022 Equity Incentive Plan, as amended.
• The options vest in four quarterly installments starting December 31, 2024, and ending September 30, 2025, contingent on continued service as a director, consultant, or service provider.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biopharmaceutical industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotechnology sector.
• The vesting schedule of quarterly installments is also a common practice to incentivize continued service.

Stakeholder Impact

• The grant of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates